Written Question · S5W-08991 · Session 5
What its position is on conducting a cost-benefit analysis of the introduction of antibiotic tests in the primary care sector, and whether …
The question
To ask the Scottish Government what its position is on conducting a cost-benefit analysis of the introduction of antibiotic tests in the primary care sector, and whether it has assessed the effectiveness of such testing in other countries.
The answer
Prescribing of systemic antibacterials in primary care has reduced for the third year running and we continue to take forward plans to limit the threat of immunity to antibiotics and drug resistance in Scotland.
Scotland’s work on Antimicrobial Resistance (AMR) is globally recognised. However, Antimicrobial Resistance is a global phenomenon and the UK is taking a cross-Government approach to tackling the problem.
As tackling AMR remains a priority and a constant challenge we are working with stakeholders through our Controlling Antimicrobial Resistance Scotland (CARS) group and Scottish Antimicrobial Prescribing Group (SAPG) in a bid to reduce inappropriate prescribing of antibiotics in all healthcare settings.
We are aware of several published studies on the cost-benefit analysis of the
C-Reactive Protein (CRP) test that have been conducted in other countries. In Scotland, whilst a pilot study of the test has been undertaken, a cost-benefit analysis has not yet been completed. However, discussions on cost-benefit of the test to NHS Scotland are currently taking place.
Scotland’s work on Antimicrobial Resistance (AMR) is globally recognised. However, Antimicrobial Resistance is a global phenomenon and the UK is taking a cross-Government approach to tackling the problem.
As tackling AMR remains a priority and a constant challenge we are working with stakeholders through our Controlling Antimicrobial Resistance Scotland (CARS) group and Scottish Antimicrobial Prescribing Group (SAPG) in a bid to reduce inappropriate prescribing of antibiotics in all healthcare settings.
We are aware of several published studies on the cost-benefit analysis of the
C-Reactive Protein (CRP) test that have been conducted in other countries. In Scotland, whilst a pilot study of the test has been undertaken, a cost-benefit analysis has not yet been completed. However, discussions on cost-benefit of the test to NHS Scotland are currently taking place.
In the Official Report
No contribution in the Official Report cites S5W-08991 by reference.